Company Description

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors.

The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.

MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma, Inc.

Country	United States
Founded	2000
IPO Date	Dec 19, 2003
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Justin File

Contact Details

Address: 9920 Pacific Heights Blvd., Suite 150 San Diego, California 92121 United States
Phone	(858) 369-7100
Website	meipharma.com

Stock Details

Ticker Symbol	MEIP
Exchange	NASDAQ
Fiscal Year	July - June
Reporting Currency	USD
CIK Code	0001262104
CUSIP Number	55279B202
ISIN Number	US55279B3015
Employer ID	51-0407811
SIC Code	2834

Key Executives

Name	Position
Yomara Gomez-Naiden	Senior Vice President of Operations and Quality
Nicole Chyoko Iida	Vice President of Legal Affairs
Anne Frese	Chief People Officer
Dr. Robert D. Mass	Strategic Advisor
David A. Walsey J.D., L.L.M.	Senior Vice President of Corporate Affairs

Latest SEC Filings

Date	Type	Title
Nov 14, 2024	8-K	Current Report
Nov 12, 2024	10-Q	Quarterly Report
Oct 25, 2024	8-K	Current Report
Sep 19, 2024	10-K	Annual Report
Sep 19, 2024	8-K	Current Report
Aug 2, 2024	8-K	Current Report
Jul 30, 2024	8-K	Current Report
Jul 22, 2024	8-K	Current Report
Jul 22, 2024	144	Filing
Jun 25, 2024	8-K	Current Report

View All SEC Filings